A direct comparison of long‐ and short‐acting GLP‐1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

T‐emerge 2 was a randomized, open‐label, 24‐week trial comparing subcutaneous taspoglutide 10 mg weekly (Taspo10), taspoglutide 20 mg weekly (Taspo20; titrated after 4 weeks of Taspo10), with exenatide 10 mcg BID (Exe; after 4 weeks of Exe 5 mcg) in patients inadequately controlled on metformin, a thiazolidinedione, or both. T‐emerge 2 showed that once‐weekly Taspo provided better glycaemic control than Exe. This report focuses on a subset of T‐emerge 2 participants undergoing a standardized liquid meal comparing Taspo to Exe, which has been previously shown to lower postprandial glucose.

[1]  Amalia Gastaldelli,et al.  Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. , 2013, Metabolism: clinical and experimental.

[2]  J. Rosenstock,et al.  The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes , 2013, Diabetes Care.

[3]  M. Fineman,et al.  GLP‐1 based therapies: differential effects on fasting and postprandial glucose , 2012, Diabetes, obesity & metabolism.

[4]  E. Ferrannini,et al.  Direct effect of GLP-1 infusion on endogenous glucose production in humans , 2012, Diabetologia.

[5]  J. Rosenstock,et al.  TheFateofTaspoglutide , aWeeklyGLP-1 Receptor Agonist , Versus Twice-Daily Exenatide for Type 2 Diabetes The T-Emerge 2 Trial , 2012 .

[6]  M. Vivarelli,et al.  Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[7]  J. Holst,et al.  An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future , 2011, Diabetes, obesity & metabolism.

[8]  R. DeFronzo,et al.  Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  T. Heise,et al.  Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once‐weekly, human GLP‐1 analogue, after single‐dose administration in patients with Type 2 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[10]  P. Cryer,et al.  β-Cell–Mediated Signaling Predominates Over Direct α-Cell Signaling in the Regulation of Glucagon Secretion in Humans , 2009, Diabetes Care.

[11]  R. Berria,et al.  Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone , 2009, Diabetes Care.

[12]  M. Taskinen,et al.  One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients , 2009, Diabetes Care.

[13]  P. Cryer,et al.  Beta-Cell-Mediated Signaling Predominates Over Direct Alpha-Cell Signaling in the Regulation of Glucagon Secretion in Humans , 2009 .

[14]  M. Horowitz,et al.  Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes , 2008, Regulatory Peptides.

[15]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[16]  R. DeFronzo,et al.  Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. , 2008, American journal of physiology. Endocrinology and metabolism.

[17]  D. Edgerton,et al.  Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. , 2008, American journal of physiology. Endocrinology and metabolism.

[18]  R. DeFronzo,et al.  Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. , 2008, Current medical research and opinion.

[19]  M. Matsuda,et al.  Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test , 2007, Diabetes Care.

[20]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[21]  J. Holst,et al.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[22]  M. Matsuda,et al.  Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study , 2003, Diabetologia.

[23]  R. Rizza,et al.  Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans , 2003, Diabetologia.

[24]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[25]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  P. Damsbo,et al.  Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. , 2001, Diabetes care.

[27]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[28]  Jeppe Sturis,et al.  Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance , 1992, Diabetes.

[29]  R. Unger,et al.  Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.